Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Gunjan L. Shah, MD, Heather Landau, MD, Caitlin Sarubbi, A.B, Ryan Schofield, MS, Andrew Lin, PharmD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Sean M. Devlin, PhD, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD

Blood (2017) 130 (Supplement 1): 3296.

https://doi.org/10.1182/blood.V130.Suppl_1.3296.3296

Published: 2017

Journal Articles

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Cindy Varga, MD BSc, Angela Dispenzieri, MD, Morie A. Gertz, MD, Stacey A Goodman, MD MS, Kristen Hsu, Leslie Inker, MD, Heather Landau, MD, Nelson Leung, MD, Joseph R. Mikhael, MD, Taimur Sher, MD, Brendan M Weiss, MD, Sandy W. Wong, MD, Jeffrey A Zonder, MD, Raymond L. Comenzo, MD

Blood (2017) 130 (Supplement 1): 5437.

https://doi.org/10.1182/blood.V130.Suppl_1.5437.5437

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde, MD, Sham Mailankody, MBBS, Eric L Smith, MDPhD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Alexander Lesokhin, MD, Malin Hultcrantz, MD, David J. Chung, MDPhD, Gunjan L. Shah, MD, Guenther Koehne, MDPhD, Heather Landau, MD, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Donna Mastey, RN, Nicole Evancha, Sean M. Devlin, PhD, Ola Landgren, MD PhD

Blood (2017) 130 (Supplement 1): 3133.

https://doi.org/10.1182/blood.V130.Suppl_1.3133.3133

Published: 2017

Journal Articles

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Galina G. Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey A Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, PhD, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 1838.

https://doi.org/10.1182/blood.V130.Suppl_1.1838.1838

Published: 2017

Journal Articles

Clinical and Pathological Features of B-Cell Acute Lymphoblastic Leukemia Following Maintenance Treatment with Lenalidomide for Multiple Myeloma

Mark Blaine Geyer, MD, Brian C. Shaffer, MD, Heather Landau, MD, Hani Hassoun, MD, Christopher Famulare, MS, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Maria E. Arcila, Jae H. Park, MD

Blood (2017) 130 (Supplement 1): 1285.

https://doi.org/10.1182/blood.V130.Suppl_1.1285.1285

Published: 2017

Journal Articles

Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with Multiple Myeloma

Hani Hassoun, MD, Rosalynn Ruiz, BS, Murata Kazunori, PhD, Kathleen Azzi, Sean Devlin, PhD, Brittany Cooper, BS, Nikoletta Lendvai, MD PhD, Heather Landau, MD, Alexander M. Lesokhin, MD, David J Chung, MD PhD, Sham Mailankody, MD, Neha S Korde, MD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2016) 128 (22): 5626.

https://doi.org/10.1182/blood.V128.22.5626.5626

Published: 2016

Journal Articles

Immunophenotypic Evidence for Reactive Polyclonal Marrow Plasmacytosis in Multiple Myeloma Patients Receiving Long-Term Lenalidomide Therapy

Hani Hassoun, MD, Mikhail Roshal, MD PhD, Joshua Sabari, MD, Brittany Cooper, BS, James Nguyen, BS, Rosalyn Ruiz, BS, Qi Gao, Heather Landau, MD, Nikoletta Lendvai, MD PhD, David J. Chung, MD PhD, Alexander M. Lesokhin, MD, Neha S Korde, MD, Sham Mailankody, MD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2016) 128 (22): 5605.

https://doi.org/10.1182/blood.V128.22.5605.5605

Published: 2016

Journal Articles

Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution

Heather Landau, MD, Jun Fan, Sergio A. Giralt, MD, Jonathan U. Peled, MD PhD, Hani Hassoun, MD, Alexander M. Lesokhin, MD, Nikoletta Lendvai, MD PhD, Neha S Korde, MD, Sham Mailankody, MD, David J. Chung, MD PhD, Guenther Koehne, MD PhD, Eric L. Smith, MD PhD, Elli Papaemmanuil, PhD, Ola Landgren, MD PhD, Christine Iacobuzio-Donahue

Blood (2016) 128 (22): 2090.

https://doi.org/10.1182/blood.V128.22.2090.2090

Published: 2016

Journal Articles

The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction

Michaela Liedtke, MD, Giampaolo Merlini, MD, Heather Landau, MD, Raymond L. Comenzo, MD, Vaishali Sanchorawala, MD, Brendan M. Weiss, MD, Jeffrey A. Zonder, MD, Jackie Walling, MBChB, PhD, Gene G. Kinney, PhD, Martin Koller, MD MPH, Morie A. Gertz, MD MACP

Blood (2016) 128 (22): 5690.

https://doi.org/10.1182/blood.V128.22.5690.5690

Published: 2016

Journal Articles

NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study

Morie A. Gertz, MD MACP, Raymond L. Comenzo, MD, Heather Landau, MD, Vaishali Sanchorawala, MD, Brendan M. Weiss, MD, Jeffrey A. Zonder, MD, Jackie Walling, MBChB, PhD, Gene G. Kinney, PhD, Martin Koller, MD MPH, Dale B. Schenk, PhD, Spencer D. Guthrie, MBA, Enchi Liu, PhD, Michaela Liedtke, MD

Blood (2016) 128 (22): 644.

https://doi.org/10.1182/blood.V128.22.644.644

Published: 2016

Journal Articles

Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Adam D. Cohen, MD, Heather Landau, MD, Emma C. Scott, MD, Michaela Liedtke, MD, Jonathan L. Kaufman, MD, Michael Rosenzweig, MD, Cristina Gasparetto, MD, David H. Vesole, MD PhD, Vaishali Sanchorawala, MD, Suzanne Lentzsch, MD PhD, Christina L. Gomes, MD, Raymond L. Comenzo, MD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 645.

https://doi.org/10.1182/blood.V128.22.645.645

Published: 2016

Journal Articles

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD PhD, Heather Landau, MD, Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Donna Salzman, MD, Ayman Saad, MD, Racquel Innis-Shelton, MD, Mehdi Hamadani, MD, Roni Tamari, MD, Kelly N. Godby, MD, Vladimir Petrovic, Lisa Williams, RN, Evelyn Orlando, Pamela M Dixon, RN, Sergio A. Giralt, MD

Blood (2016) 128 (22): 4630.

https://doi.org/10.1182/blood.V128.22.4630.4630

Published: 2016

Journal Articles

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

Galina Grigoriev Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2016) 128 (22): 4523.

https://doi.org/10.1182/blood.V128.22.4523.4523

Published: 2016

Journal Articles

Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

Michaela Liedtke, MD, Raymond L. Comenzo, MD, Heather Landau, MD, Vaishali Sanchorawala, MD, Brendan M. Weiss, MD, Jeffrey A. Zonder, MD, Jackie Walling, MBChB, PhD, Gene G. Kinney, PhD, Martin Koller, MD MPH, Dale B. Schenk, PhD, Spencer D. Guthrie, MBA, Enchi Liu, PhD, Morie A. Gertz, MD MACP

Blood (2016) 128 (22): 647.

https://doi.org/10.1182/blood.V128.22.647.647

Published: 2016

Journal Articles

Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study

Heather Landau, MD, Nicole Montanez, BS, Alexandra Cowan, MS, Hoover Elizabeth, BS, Carlos Flombaum, MD, Jennifer Liu, MD, Mat Maurer, MD, Nikoletta Lendvai, MD PhD, Ola Landgren, MD PhD, Sergio A. Giralt, MD, Hani Hassoun, MD

Blood (2015) 126 (23): 3178.

https://doi.org/10.1182/blood.V126.23.3178.3178

Published: 2015

Journal Articles

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Sandy W. Wong, MD, Giovanni Palladini, MD PhD, Ute Hegenbart, MD, Heather Landau, MD, Melissa Warner, BS, Arnaud Jaccard, MD PhD, Herve Avet-Loiseau, Timon Hansen, MD, Joan Bladé, MD, María Teresa Cibeira, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 3049.

https://doi.org/10.1182/blood.V126.23.3049.3049

Published: 2015

Journal Articles

Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

Nikoletta Lendvai, MDPhD, Sean Devlin, PhD, Minal Patel, BA, Kristina Marie Knapp, Daniel Ekman, Ida Grundberg, David J Chung, MDPhD, Hani Hassoun, MD, Guenther Koehne, MDPhD, Alexander M. Lesokhin, MD, Heather Landau, MD, Sergio A. Giralt, MD, Neha S Korde, MD, Ola Landgren, MD PhD

Blood (2015) 126 (23): 4257.

https://doi.org/10.1182/blood.V126.23.4257.4257

Published: 2015

Journal Articles

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Blood (2015) 126 (23): 4332.

https://doi.org/10.1182/blood.V126.23.4332.4332

Published: 2015

Journal Articles

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Suzanne Lentzsch, Nicolas Villanueva, MD, James Nguyen, BS, Heather Landau, MD, Nikoletta Lendvai, MDPhD, Susanna Miao, BA, Jordan M. Schecter, MD, Mariamne Reyna, BS, Markus Y Mapara, MD PhD, Robert L. Redner, MD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Tarun Kewalramani, MD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Ola Landgren, MD PhD, Hani Hassoun, MD

Blood (2015) 126 (23): 1975.

https://doi.org/10.1182/blood.V126.23.1975.1975

Published: 2015

NARROW

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Clinical and Pathological Features of B-Cell Acute Lymphoblastic Leukemia Following Maintenance Treatment with Lenalidomide for Multiple Myeloma

Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with Multiple Myeloma

Immunophenotypic Evidence for Reactive Polyclonal Marrow Plasmacytosis in Multiple Myeloma Patients Receiving Long-Term Lenalidomide Therapy

Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution

The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction

NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study

Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only